MORE THAN DOUBLING OF COSTS WITH UNCHANGED 12-MONTH MORTALITY IN INCIDENT METASTATIC PROSTATE CANCER IN GERMANY, 2011-2024
Author(s)
Stefano Tagliabue, MSc1, Thomas Wilke, PhD2, Benjamin Birkner, Dr.3, Antje Mevius, MA2, Barthold Deiters, Dr.4, Sabrina Müller, MSc1.
1GIPAM GmbH, Wismar, Germany, 2IPAM e.V., Wismar, Germany, 3GWQ ServicePlus AG, Hamburg, Germany, 4GWQ ServicePlus AG, Düsseldorf, Germany.
1GIPAM GmbH, Wismar, Germany, 2IPAM e.V., Wismar, Germany, 3GWQ ServicePlus AG, Hamburg, Germany, 4GWQ ServicePlus AG, Düsseldorf, Germany.
OBJECTIVES: To describe trends in age- and sex-standardized 12-month overall survival (OS) and inflation-adjusted costs among patients with incident metastatic prostate cancer (mPC) in anonymized German statutory health insurance claims data from 2011 to 2024.
METHODS: Patients with mPC were identified using ICD-10-GM diagnosis codes: C61 (PC) and C77-C79 for metastatic disease. Metastatic disease was required to occur within ±3 months of the qualifying PC diagnosis, with no evidence of mPC during a 1-year baseline period. Age- and sex-standardized 12-month OS, standardized to the overall German statutory health insurance population, was assessed from the date of incident mPC (index date). Fourteen annual cohorts were defined according to index date year of each patient (2011-2024). Inflation-adjusted all-cause healthcare costs were measured over the 12-month post-index period for each patient and reported by index-year cohort. Trends in OS and costs were evaluated over time, using 2011 as the reference year.
RESULTS: The cohort included 202 patients in 2011, peaked at 550 in 2023, and included 175 patients in 2024; mean age increased from 70.7 to 72.3 years. Age-standardized 12-month OS ranged from 85.0% to 94.3% and remained nearly unchanged between index years 2011/12 (91.0%/93.9%) and 2023/2024 (94.5%/91.2%). In contrast, costs more than doubled from €17,913 to €36,327 per patient, reaching >200% of the 2011 level by 2024. Costs excluding the final 4 weeks before death increased from €16,780 to €34,471. Cost composition shifted substantially from inpatient care toward outpatient drug costs: drug spending rose from €5,168 to €19,439, and drug share increased from 28.9% to 53.5%.
CONCLUSIONS: In incident mPC, standardized 12-month OS showed no meaningful improvement, while costs more than doubled and shifted strongly toward outpatient drug spending.
METHODS: Patients with mPC were identified using ICD-10-GM diagnosis codes: C61 (PC) and C77-C79 for metastatic disease. Metastatic disease was required to occur within ±3 months of the qualifying PC diagnosis, with no evidence of mPC during a 1-year baseline period. Age- and sex-standardized 12-month OS, standardized to the overall German statutory health insurance population, was assessed from the date of incident mPC (index date). Fourteen annual cohorts were defined according to index date year of each patient (2011-2024). Inflation-adjusted all-cause healthcare costs were measured over the 12-month post-index period for each patient and reported by index-year cohort. Trends in OS and costs were evaluated over time, using 2011 as the reference year.
RESULTS: The cohort included 202 patients in 2011, peaked at 550 in 2023, and included 175 patients in 2024; mean age increased from 70.7 to 72.3 years. Age-standardized 12-month OS ranged from 85.0% to 94.3% and remained nearly unchanged between index years 2011/12 (91.0%/93.9%) and 2023/2024 (94.5%/91.2%). In contrast, costs more than doubled from €17,913 to €36,327 per patient, reaching >200% of the 2011 level by 2024. Costs excluding the final 4 weeks before death increased from €16,780 to €34,471. Cost composition shifted substantially from inpatient care toward outpatient drug costs: drug spending rose from €5,168 to €19,439, and drug share increased from 28.9% to 53.5%.
CONCLUSIONS: In incident mPC, standardized 12-month OS showed no meaningful improvement, while costs more than doubled and shifted strongly toward outpatient drug spending.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE701
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology